In the past 2 years, the US Food and Drug Administration (FDA) has approved 2 drugs for treating MASH, and bariatric surgical and endoscopic treatments are available as well
Beyond weight loss, retatrutide's glucagon receptor activity may theoretically offer advantages for women with metabolic dysfunction-associated steatotic liver disease (MASLD, previously termed non-alcoholic fatty liver disease or NAFLD) or its more severe form, metabolic dysfunction-associated steatohepatitis (MASH, previously NASH)
Stopping completely may gradually return skin to its baseline tone
Consulting a healthcare provider ensures the therapy matches individual health goals and needs
and TAP, to help correct the look of persistent discoloration for a more luminous, even complexion
Tell us what youve tried and what you want to change